Skip to content

Study · Randomized controlled trial · n = 52 · 2019

2 results

The influence of oxytocin on risk-taking in the balloon analogue risk task among women with bulimia nervosa and binge eating disorder.

Leslie M, Leppanen J, Paloyelis Y, Nazar BP, Treasure J

Journal of neuroendocrinology23 Jul 2019Cited by 21 (Europe PMC)

PMID31283053 (opens in a new tab)DOI10.1111/jne.12771 (opens in a new tab)PepBankPUB-31283053
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with bulimia nervosa or binge eating disorder and healthy women, oxytocin had no main effect on performance in the Balloon Analogue Risk Task.

    In plain wordsIn women with and without eating disorders, oxytocin did not change overall performance on a risk-taking task compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeBalloon Analogue Risk Task performance, main effect of oxytocin
    Study

    n = 52

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    64 IU divided doseAs given in this study (human).

    Source sentences

    Summary
    Oxytocin did not have a main effect on performance in the BART (F = 0.01, df = 1, P = .907, η2partial  < 0.001)
    2 context sentences
    Summary · context
    The present study aimed to test this hypothesis by administering the Balloon Analogue Risk Task (BART) to 25 women with BN or BED and 27 healthy comparison women without a history of an eating disorder.
    Summary · context
    Furthermore, we tested the effect of a divided dose of 64 IU of oxytocin on risk-taking behaviour in the BART.
  2. 02HumanRandomized controlled trialEfficacy outcome

    Under oxytocin, women with bulimia nervosa or binge eating disorder behaved more safely on the Balloon Analogue Risk Task than healthy women did, but not under placebo.

    In plain wordsUnder oxytocin, women with eating disorders took fewer risks than healthy women on a task, but not under placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseBalloon Analogue Risk Task performance, group by oxytocin interaction
    Study

    n = 52

    Comparator
    Placebo; healthy comparison group
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    64 IU divided doseAs given in this study (human).

    Source sentences

    Summary
    there was an interaction, such that participants in the BN/BED participant group, compared to the healthy comparison group, demonstrated safer behaviour on the BART in the oxytocin condition, but not in the placebo condition (F = 4.29, df = 1, P = 0.044, η2partial  = 0.082).
    2 context sentences
    Summary · context
    The present study aimed to test this hypothesis by administering the Balloon Analogue Risk Task (BART) to 25 women with BN or BED and 27 healthy comparison women without a history of an eating disorder.
    Summary · context
    Furthermore, we tested the effect of a divided dose of 64 IU of oxytocin on risk-taking behaviour in the BART.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.